Serum Gamma-Glutamyltransferase Activity: Inhibitory Study in Patient of Hepatitis

Namama S. Talabani

Abstract—Elevation of gamma-glutamyltransferase (GGT) activity has been implicated in many pathologies, and clinical inhibitors of GGT are under development for use in the treatment of liver, cancer, bone, and other diseases. In this study we try to find other new inhibitor of GGT, we used new polar amino acid (threonine) as inhibitor, kinetic studies provide insight into the mechanism of inhibition. New uncompetitive inhibitors of physiological GGT reaction we found, development of new inhibitors is essential for exploiting GGT as a therapeutic target. L-threonine, in the presence study was detected as uncompetitive inhibitor, Km values were determined; we characterized the kinetic properties of GGT under a standard set of condition. Serum GGT was analyzed in healthy cases (normal 25: mean±SD) age 30±12 years, (16.71±0.87), the mean values of GGT levels were statistically significantly higher in liver syndrome (70.79±1.24), and this values decreased in the presence of inhibitor to (60.82±0.87).

Keywords—Gamma-glutamyltransferase, inhibitor, threonine, hepatitis.

I. INTRODUCTION

GGT (EC.2.3.2.2) is a cell surface enzyme that cleaves gamma-glutamyl bonds of extracellular substances including glutathione (GSH), GSH s-conjugates and leukotriene C (Elce and Broxmeyer, 1976; Curthoys and Hughey, 1979; Wickham, West, et al, 2011).

Elevation of serum γ-glutamyltransferase (GGT) activity is frequently interpreted as an index of hepatobiliary dysfunction and as a nonspecific marker of excessive alcohol use (J.B. Whitifield, 2001). And elevation of GGT has been implicated in pulmonary disease, cardiovascular disease and cancer (Lowry, Allister et al, 2008; Lee, Evan et al, 2007; Hanigan, Gallagher et al, 1999)

GGT has been demonstrated in various human and animal organs, including kidneys, liver and spleen. It is also present in various body fluids, such as saliva, serum, bile and urine (Sener, 1997; Nemesanzky and lott, 1985). GGT is present in serum as part of several molecular complexes, with distinct physiochemical properties (Huseby, 1982; Wenham, Hornet al, 1984).

GGT measurement was introduced into clinical laboratories some 45 years ago, and over that times a large amount of information on factors influencing its activity in serum has accumulated. Theories have been put forward about its normal function within the body and its role in numerous pathological conditions.

Threonine is an an α-amino acid, this essential amino acid is classified as polar (Moss, 1984), while the highest growth and specific growth and specific growth rate were showed in diet containing 1.7% threonine. Dietary threonine imbalance is known to reduce the growth of the small intestine, liver, and skeletal muscle in young animals, an excess or a deficiency of dietary threonine decreases protein synthesis in rapidly growing tissues (Xu, Shiyan et al, 2007; Benakappa and Varghese, 2013).

The present work, we have investigated the inhibitory effect of essential amino acid (L-threonine) on serum GGT activity in patients with hepatitis, at the same time we study the effect of time on the activity, the results would help to select the new inhibitor which might useful for the treatment of some hepatitis.

II. MATERIALS AND METHODS

A. Collection of samples

Blood analysis is usually done on venous of capillary blood. (45) samples of blood were throughout the investigation of GGT enzyme activity (age 20-50 years), these samples were diagnosed by consultants and proved by liver function test. They are no accompanied disease. Healthy normal (25) were used as controls.

The blood left at room temperature after clot formation the serum isolated by centrifugation. serum obtained was use on the same day of experiment.

B. Chemicals

These were chosen for specific GGT activity determination and all other experiments related, they were of analytical grade, and highly purified, purchased from BDH and FLUKA.

C. Gamma-glutamyltransferase assay

The GGT activity was determined by the hydrolysis of g-glutamyl p-nitroanilide in the presence of the acceptor (Szasz, 1969; 1974). Standard assay included final reagent concentration 2mM of gamma-glutamyl p-nitroanilide, 62 mM of glycerylglycine and 95 mM of Tris-HCl, pH 8.1. The rate of p-nitroanilide formation was measured at 405 nm by using spectrophotometer. The results were expressed as U/L, one unit of enzyme represents the amount of enzyme that catalyzes the release of 1mmol of nitroaniline/min.

Namama S. Talabani is with University of Sulaimania-Faculty of Science-Chemistry department Email.sareaali@hotmail.com.
Inhibition studies

The GGT inhibition with L-threonine was studied by using Tris-HCl buffer containing various concentrations of gamma-glutamyl p-nitroanilide (0.5, 1.5, 2, 2.5, 3 mmol/L) and 62 mmol of glycylglycine per liter. L-threonine (2.5 mM) was added to the reaction mixture. The GGT activities were assayed after 1 min incubation with the inhibitors.

Apparent Km and apparent Vmax values were determined from Michaelis-Menten and Lineweaver Burk plots for gamma-glutamyl p-nitroanilide.

III. RESULTS

Investigating GGT activity data obtained shows an elevation of the activity in hepatitis (70.79±1.24 U/L) when compared with normal activity (16.71±0.87 U/L) (table I). In presence of L-threonine (2.5 mM/L) uncompetitively inhibited the serum GGT activity at 2 mmol/L concentration of gamma-glutamyl p-nitroanilide (fig 1).

A. Determination of Vmax and Km values

These values of Vmax and Km were achieved using Michaelis-Menten analysis fig(2) (table II), the data analysed were confirmed by plotting Lineweaver-burk plot fig(3). By these figures we can detect L-threonine as uncompetitive inhibitor.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>GGT activity without L-threonine</th>
<th>GGT activity in presence of L-threonine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Km (mm)</td>
<td>1.25</td>
<td>1</td>
</tr>
<tr>
<td>Vmax (U/L)</td>
<td>12.5</td>
<td>10</td>
</tr>
</tbody>
</table>

IV. DISCUSSION

Our results showed that L-threonine could affect activity of GGT enzyme. Data from our study indicate that L-threonine amino acid inhibited the activity of GGT enzyme.

Elevation of GGT activity can be explained to be due to the affection of liver by damage of liver cells. The relationship between hepatic and serum GGT in human patients has been studied by several authors. Experimental work has mostly used rats. Who have substantially lower serum and hepatic GGT activity than humans(Teschke et al., 1983). found 20 fold higher values in normal humans than in control rats. As so much work is based on these animals, the assumption that the difference is purely quantitative is rather a crucial one.
A sensitive method for measurement of GGT activity in needle biopsy samples was developed by (Satoh and Colleagues;1980),found that in 57 patients with a variety of liver diseases either serum or hepatic GGT. or both, or neither, could be elevated . Among those patients with both serum and liver GGT increased, higher values were found in alcoholic or drug-induced hepatitis than in viral hepatitis, and in the former group serum GGT showed a greater increase above normal (approximately six fold) than liver GGT (around three fold).

In the study with S.GGT, it was reported that for gamma-glutamyl p-nitroanilide and glycglycin, the Km values were 1.9 mM and 12.0 mM respectively (Rosalki and Tarlow,1974). The Km value of human liver GGT, when gamma-glutamyl p-nitroanilide was used as the substrate, was reported as 1.4 mM, and for kidney it was 1.2 mM( Shaw et al,1978).

It was reported in the literature that L-serine (which is another essential amino acid) inhibits GGT in the presence of borate by interacting with the gamma-glutamyl binding site of the enzyme(Tate and Meister,1978; Vesely et al,1985). GGT activity is increased in a number of primary and metastatic tumors(Dominici et al,2003). It has been shown that hepatocellular carcinoma can be expressed hepatoma specific GGT and secreted GGT in to circulating blood(Yao et al,1998).

In the conclusion, our experiment demonstrated that L-threonine amino acid, or food that contain this type of amino acid might provide to be a valuable tool for the treatment of liver diseases.

REFERENCES